{Reference Type}: Journal Article
{Title}: The Need for Classification Criteria of Immune Checkpoint Inhibitor-induced inflammatory Arthritis: A Scoping Review.
{Author}: Ghosh N;Jivanelli B;Couette N;Singh N;Kostine M;Simon Meara A;Liew DFL;
{Journal}: Rheum Dis Clin North Am
{Volume}: 50
{Issue}: 2
{Year}: 2024 May
{Factor}: 2.032
{DOI}: 10.1016/j.rdc.2024.02.006
{Abstract}: Immune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is an immune-related adverse event that can occur as a result of receiving ICIs for cancer treatment. Thus far, ICI-IA has been described variably in the literature, in part due to varying presentations that evolve over time, as well as a lack of standardized definitions and classification. This scoping review aggregates various descriptions of ICI-IA, highlighting the most prominent attributes of ICI-IA from categories such as symptoms, signs, imaging, and laboratory findings as well as discussing potential mimic conditions.